Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trialThomas Powles, Felipe Reyes, D. Cascallar et al.|The Lancet Oncology|2021Cited by 645